Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Shi, Ying ^a   Lai, Xiangru ^a   Ye, Lingyan ^a   Chen, Keqiang ^b   Cao, Zheng ^a   Gong, Wanghua ^b   Jin, Lili ^a   Wang, Chunyan ^b,c   Liu, Mingyong ^b,d   Liao, Yuan ^a   Wang, Ji Ming ^b   Zhou, Naiming ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Xuzhou Yes Biotech Laboratories Ltd   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; AUTACOID; CHEMOTACTIC FACTOR; FORMYLMETHIONYLLEUCYLPHENYLALANINE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; HCAR2 PROTEIN, MOUSE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC ACID; NICOTINIC RECEPTOR; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ANIMAL; CELL MOTION; CHEMOTAXIS; CYTOLOGY; DRUG EFFECT; ENDOCYTOSIS; HEK293 CELL LINE; HUMAN; MACROPHAGE; MAPK SIGNALING; METABOLISM; MOUSE; PATHOLOGY; RAW 264.7 CELL LINE; SECRETION (PROCESS); SEPSIS; UPREGULATION;

ACTINS; ANIMALS; CELL MOVEMENT; CHEMOKINE CCL2; CHEMOTACTIC FACTORS; CHEMOTAXIS; ENDOCYTOSIS; GTP-BINDING PROTEIN BETA SUBUNITS; GTP-BINDING PROTEIN GAMMA SUBUNITS; HEK293 CELLS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NIACIN; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RAW 264.7 CELLS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; SEPSIS; UP-REGULATION;

EID: 85012107824     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep42279     Document Type: Article

References (71)

1. Altschul, R., Hoffer, A. & Stephen, J. D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 54, 558-559 (1955).
2. Carlson, L. A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258, 94-114 (2005).
3. Villines, T. C., Kim, A. S., Gore, R. S. & Taylor, A. J. Niacin: the evidence, clinical use, and future directions. Curr Atheroscler Rep 14, 49-59 (2012).
4. Gille, A., Bodor, E. T., Ahmed, K. & Offermanns, S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 48, 79-106 (2008).
5. Lavigne, P. M. & Karas, R. The role of niacin in the aftermath of aim-high: a meta-analysis. Journal of the American College of Cardiology 59, E1687 (2012).
6. Villines, T. C. et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 55, 2721-2726 (2010).
7. Bruckert, E., Labreuche, J. & Amarenco, P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210, 353-361 (2010).
8. Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K. & Grace, K. A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
9. Brown, B. G. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345, 1583-1592 (2001).
10. Cashin-Hemphill, L. et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. Jama 264, 3013-3017 (1990).
11. Soga, T. et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 303, 364-369 (2003).
12. Tunaru, S. et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9, 352-355 (2003).
13. Wise, A. et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278, 9869-9874 (2003).
14. Offermanns, S. et al. International union of basic and clinical pharmacology. LXXXII: nomenclature and classification of hydroxycarboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacol Rev 63, 269-290 (2011).
15. Taggart, A. K. et al. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 280, 26649-26652 (2005).
16. Digby, J. E., Lee, J. M. & Choudhury, R. P. Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol 20, 321-326 (2009).
17. Lauring, B. et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med 4, 148ra115 (2012).
18. Lukasova, M., Malaval, C., Gille, A., Kero, J. & Offermanns, S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 121, 1163-1173 (2011).
19. Yousefi, S., Cooper, P. R., Mueck, B., Potter, S. L. & Jarai, G. cDNA representational difference analysis of human neutrophils stimulated by GM-CSF. Biochem Biophys Res Commun 277, 401-409 (2000).
20. Schaub, A., Futterer, A. & Pfeffer, K. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol 31, 3714-3725 (2001).
21. Hanson, J. et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest 120, 2910-2919 (2010).
22. Libby, P., Okamoto, Y., Rocha, V. Z. & Folco, E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 74, 213-220 (2010).
23. Digby, J. E. et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol 32, 669-676 (2012).
24. Tacke, F. et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 117, 185-194 (2007).
25. Mahabadi, A. A. et al. Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis 211, 195-199 (2010).
26. Wu, B. J. et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol 30, 968-975 (2010).
27. Mitrofanov, V. A., Ovchinnikova, N. M., Belova, S. V., Fedotova, M. V. & Gladkova, E. V. Inflammatory degeneration of joint tissue in adjuvant arthritis after intraarticular treatment with the mixture of silver drug and nicotinic acid. Bull Exp Biol Med 140, 702-704 (2005).
28. Cho, K. H., Kim, H. J., Rodriguez-Iturbe, B. & Vaziri, N. D. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am J Physiol Renal Physiol 297, F106-113 (2009).
29. Shehadah, A. et al. Niaspan treatment induces neuroprotection after stroke. Neurobiol Dis 40, 277-283 (2010).
30. Kwon, W. Y., Suh, G. J., Kim, K. S. & Kwak, Y. H. Niacin attenuates lung inflammation and improves survival during sepsis by downregulating the nuclear factor-kappaB pathway. Crit Care Med 39, 328-334 (2011).
31. Rahman, M. et al. The β -hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun 5, 3944 (2014).
32. Chen, H. et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. The Journal of clinical investigation 124, 2188-2192 (2014).
33. Gaidarov, I. et al. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential. Cell Signal 25, 2003-2016 (2013).
34. Zandi-Nejad, K. et al. The role of HCA2 (GPR109A) in regulating macrophage function. Faseb J 27, 4366-4374 (2013).
35. Li, G. et al. Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3. J Biol Chem 285, 22605-22618 (2010).
36. Li, G. et al. Distinct kinetic and spatial patterns of protein kinase C (PKC)- and epidermal growth factor receptor (EGFR)-dependent activation of extracellular signal-regulated kinases 1 and 2 by human nicotinic acid receptor GPR109A. J Biol Chem 286, 31199-31212 (2011).
37. Jin, T., Zhang, N., Long, Y., Parent, C. A. & Devreotes, P. N. Localization of the G protein betagamma complex in living cells during chemotaxis. Science 287, 1034-6 (2000).
38. English, J. et al. New Insights into the Control of MAP Kinase Pathways. Experimental Cell Research 253, 255-270 (1999).
39. Stephens, L., Ellson, C. & Hawkins, P. Roles of PI3Ks in leukocyte chemotaxis and phagocytosis. Current Opinion in Cell Biology 14, 203-213 (2002).
40. Zhang, N. et al. Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. Blood 108, 38-44 (2006).
41. Maciejewski-Lenoir, D. et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 126, 2637-2646 (2006).
42. Tang, H., Lu, J. Y., Zheng, X., Yang, Y. & Reagan, J. D. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun 375, 562-565 (2008).
43. Zimmerman, M. A. et al. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol 302, G1405-1415 (2012).
44. Singh, N. et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40, 128-139 (2014).
45. Jones, G. E. Cellular signaling in macrophage migration and chemotaxis. J Leukoc Biol 68, 593-602 (2000).
46. Serhan, C. N. & Savill, J. Resolution of inflammation: the beginning programs the end. Nat Immunol 6, 1191-1197 (2005).
47. Weber, C., Schober, A. & Zernecke, A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 24, 1997-2008 (2004).
48. Horuk, R. Chemokine receptors. In Offermanns S, R. W. Encyclopedic Reference of Molecular Pharmacology. 237-241 (2003).
49. Offermanns, S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 27, 384-390 (2006).
50. Hildebrandt, J. D. Role of subunit diversity in signaling by heterotrimeric G proteins. Biochem Pharmacol 54, 325-339 (1997).
51. Smrcka, A. V. G protein β γ subunits: central mediators of G protein-coupled receptor signaling. Cell Mol Life Sci 65, 2191-2214. (2008).
52. Dupré, D. J., Robitaille, M., Rebois, R. V. & Hébert, T. E. The role of Gbetagamma subunits in the organization, assembly, and function of GPCR signaling complexes. Annu Rev Pharmacol Toxicol 49, (2009).
53. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572 (2002).
54. Poon, L. S., Chan, A. S. & Wong, Y. H. Gbeta3 forms distinct dimers with specific Ggamma subunits and preferentially activates the beta3 isoform of phospholipase C. Cell Signal 21, 737-744 (2009).
55. Zhang, Y. et al. Different roles of G protein subunits β 1 and β 2 in neutrophil function revealed by gene expression silencing in primary mouse neutrophils. J Biol Chem 285, 24805-24814 (2010).
56. van Hemert, F., Lazova, M. D., Snaar-Jagaska, B. E. & Schmidt, T. Mobility of G proteins is heterogeneous and polarized during chemotaxis. J Cell Sci 123, 2922-2930 (2010).
57. Widmann, C., Gibson, S., Jarpe, M. B. & Johnson, G. L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79, 143-180 (1999).
58. Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912 (2002).
59. Huang, C., Jacobson, K. & Schaller, M. D. MAP kinases and cell migration. Journal of Cell Science 117, 4619-4628 (2004).
60. Wenzel-Seifert, K. & Seifert, R. Chemoattractant Receptor-G-Protein Coupling. in Physiology of Inflammation (Ley, K. ed.), Springer New York. pp 146-188 (2001).
61. Liu, X. et al. Bidirectional regulation of neutrophil migration by mitogen-activated protein kinases. Nat Immunol 13, 457-464 (2012).
62. Liu, Z. et al. TLR4 Signaling augments monocyte chemotaxis by regulating G protein-coupled receptor kinase 2 translocation. J Immunol 191, 857-864 (2013).
63. Ferguson, S. S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53, 1-24 (2001).
64. Finley, M. J. et al. Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor. Journal of Neuroimmunology 197, 114-123 (2008).
65. Szabo, I. et al. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization. Journal of Leukocyte Biology 74, 1074-1082(2003).
66. Deng, X. et al. Asynthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 inmonocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood 94, 1165-1173 (1999).
67. Richardson, R. M., Ali, H., Tomhave, E. D., Haribabu, B. & Snyderman, R. Cross-desensitization of chemoattractant receptors occurs at multiple levels. Evidence for a role for inhibition of phospholipase C activity. J Biol Chem 270, 27829-27833 (1995).
68. Giegold, O. et al. CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation. J Immunol 190, 3696-705 (2013).
69. Hecht, I. et al. Heterologous desensitization of T cell functions by CCR5 and CXCR4 ligands: inhibition of cellular signaling, adhesion and chemotaxis. Int. Immunol 15, 29-38 (2003).
70. Ali, H., Richardson, R. M., Haribabu, B. & Snyderman, R. Chemoattractant receptor cross-desensitization. J Biol Chem 274, 6027-6030 (1999).
71. Moulédous, L. et al. GRK2 protein-mediated transphosphorylation contributes to loss of function of m-opioid receptors induced by neuropeptide FF (NPFF2) receptors. J Biol Chem 287, 12736-12749 (2012).